☆ 4.7 Article

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis

FRONTIERS IN PUBLIC HEALTH (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

V Makker et al.

Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Nicole Concin et al.

Summary: The European consensus conference on endometrial carcinoma in 2014 aimed to produce multi-disciplinary evidence-based guidelines. Since then, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) have decided to update the guidelines and cover new topics to improve care for women with endometrial carcinoma globally.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

Add to Collection

Article Oncology

Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis

Sarah A. Ackroyd et al.

Summary: In the Markov model, first-line therapy with P/L for advanced or recurrent endometrial cancer was found to increase costs and worsen outcomes in the MSS cohort, while it improved survival and QALYs in the MSI-high cohort but was not cost-effective at the current drug cost.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis

David A. Barrington et al.

Summary: The study evaluated the cost-effectiveness of LP in patients with recurrent, pretreated endometrial cancer, showing that LP is not cost-effective compared to other treatments and a significant reduction in cost is required for it to be cost-effective.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Economics

Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer

Elizabeth Thurgar et al.

Summary: The study found that pembrolizumab is a highly cost-effective treatment option compared to chemotherapy for women with previously treated unresectable or mEC with deficient mismatch repair or high microsatellite instability. The results demonstrated substantial quality-adjusted life-years and life-year gains with pembrolizumab over chemotherapy.

JOURNAL OF MEDICAL ECONOMICS (2021)

Add to Collection

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Lenvatinib in Management of Solid Tumors

Zhonglin Hao et al.

ONCOLOGIST (2020)

Add to Collection

Article Oncology

Second-line lenvatinib in patients with recurrent endometrial cancer

Ignace Vergote et al.

GYNECOLOGIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Vicky Makker et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis

David A. Barrington et al.

GYNECOLOGIC ONCOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

Yu Kato et al.

PLOS ONE (2019)

Add to Collection

Article Oncology

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model

Takayuki Kimura et al.

CANCER SCIENCE (2018)

Add to Collection

Article Oncology

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Patrick A. Ott et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Health Care Sciences & Services

Economic Burden Associated with Adverse Events in Patients with Metastatic Melanoma

Bhakti Arondekar et al.

Journal of Managed Care & Specialty Pharmacy (2016)

Add to Collection

Article Oncology

Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer

Quang A. Le et al.

BREAST CANCER RESEARCH AND TREATMENT (2016)

Add to Collection

Article Economics

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement

Don Husereau et al.

VALUE IN HEALTH (2013)

Add to Collection

Article Health Care Sciences & Services

Improved curve fits to summary survival data: application to economic evaluation of health technologies

Martin W. Hoyle et al.

BMC MEDICAL RESEARCH METHODOLOGY (2011)

Add to Collection

Article Medicine, General & Internal

Health outcomes in economic evaluation: the QALY and utilities

Sarah J. Whitehead et al.

BRITISH MEDICAL BULLETIN (2010)

Add to Collection

Article Multidisciplinary Sciences

The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study

Joseph J. Sacco et al.

PLOS ONE (2010)

Add to Collection

Article Medicine, General & Internal

EQ-5D: a measure of health status from the EuroQol Group

R Rabin et al.

ANNALS OF MEDICINE (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.